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Retinoblastoma gene mutations in primary human bladder cancer
H Miyamoto, T Shuin, S Torigoe, Y Iwasaki and Y Kubota
Department of Urology, Yokohama City University School ofMedicine, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236, Japan.
Summary Inactivation of the retinoblastoma (RB) gene is known to be implicated in the pathogenesis of
several types of human cancers. Since structural alterations of the RB gene have not been well examined in
human bladder cancer, we looked for mutations in the entire coding region of this gene using polymerase
chain reaction (PCR) and single-strand conformational polymorphism analysis of RNA. We also examined
allelic loss of the RB gene using PCR-based restriction fragment length polymorphism analysis. Of 30 samples
obtained from patients with bladder cancer, eight (27%) were found to have RB gene mutations. DNA
sequencing of the PCR products revealed five cases with single point mutations and three cases with small
deletions. These mutations included one (10%) of ten low-grade (grade 1) tumours, four (50%) of eight
intermediate-grade (grade 2) tumours and three (25%) of 12 high-grade (grade 3) tumours. Likewise,
mutations were found in four (21%) of 19 superficial (pTa and pT1) tumours and four (36%) of 11 invasive
(pT2 or greater) tumours. In 15 informative cases, loss of heterozygosity at the RB locus was shown in five
cases (33%), three cases with RB mutations and two without them. These results suggest that RB gene
mutations are involved in low-grade and superficial bladder cancers as well as in high-grade and invasive
cancers.
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The retinoblastoma (RB) susceptibility gene was the first
tumour-suppressor gene isolated, is located on human
chromosome 13ql4 (Sparkes et al., 1980) and consists of 27
exons (McGee et al., 1989). This gene encodes a nuclear
phosphoprotein that regulates the cell cycle and forms pro-
tein complexes with the adenovirus ElA and SV40 large T
oncoproteins (Goodrich et al., 1991). Functional loss of the
RB gene is thought to be involved in the initiation and/or
progression of many human cancers.
Various studies have revealed that the inactivation of the
RB gene has important roles in the development of several
types of human tumours, including retinoblastoma (Friend et
al., 1986; Fung et al., 1987; Lee et al., 1987), osteosarcoma
(Friend et al., 1986; Fung et al., 1987; Toguchida et al.,
1988), lung cancer (Harbour et al., 1988; Yandell et al., 1989;
Horowitz et al., 1990; Mori et al., 1990), breast cancer
(T'Ang et al., 1988; Varley et al., 1989) and prostate cancer
(Bookstein et al., 1990). Similarly, several studies have re-
vealed that human bladder cancers have altered or absent RB
protein, or loss of heterozygosity (LOH) at the RB locus
(Horowitz et al., 1990; Cairns et al., 1991; Ishikawa et al.,
1991: Presti et al., 1991; Xu et al., 1993). Takahashi et al.
(1991) and Goodrich et al. (1992) showed that the RB gene
transfected into bladder cancer cells suppressed tumori-
genicity, suggesting this gene is critical in bladder cancer
development. Xu et al. (1993) showed alteration of RB pro-
tein expression in human bladder cancers by immunohisto-
chemical staining. They also demonstrated that loss of RB
protein expression is correlated with LOH at the RB locus.
However, structural alterations of the RB gene have not been
well examined. In this study, we used the recently developed
method of single-strand conformational polymorphism ana-
lysis of RNA (RNA-SSCP) (Danenberg et al., 1992) and
examined alterations in the entire coding region of the RB
gene in 30 primary human bladder cancers ofdifferent grades
and stages. In addition, we examined RB-LOH using restric-
tion fragment length polymorphism (RFLP) analysis based
on the polymerase chain reaction (PCR). RB gene mutations
were found in low-grade and non-invasive bladder cancers as
well as in high-grade and invasive ones.
Materials and methods
Patients and tissues
Tissue samples of human bladder cancers were obtained from
30 patients [18 males and 12 females, 67.1 ± 14.3 years of age
(mean ± s.d.)] by transurethral cold-knife resection, and
matching normal tissue samples from heparinised venous
blood were collected at Yokohama City University and
Yokohama Municipal Citizen's Hospital. Two or three pieces
obtained from one tumour in each patient were used for
RNA and DNA analyses. The remaining tumours were fixed
and haematoxylin and eosin staining was performed for
histological diagnosis. All the tumours were histologically
diagnosed as transitional cell carcinoma. Twenty-five cases
were fresh tumours and five cases were recurrent ones after
initial transurethral surgery. None of them had been treated
with radiation or anti-cancer drugs before surgery. Detailed
clinical and histopathological data on each patient were
evaluated at the same institutions according to the General
Rule for Clinical and Pathological Studies on Bladder Cancer
(Japanese Urological Association and the Japanese
Pathological Society, 1980), which adopts the TNM
classification system of malignant tumours (Table I). All the
samples selected for this study were rapidly frozen in liquid
nitrogen and stored at
-80°C until RNA or DNA was
extracted. Written informed consent was obtained from each
patient according to the guidelines of the Human Subjects
Reviews Committee.
RNA extraction, PCR and RNA-SSCP
Total cellular RNAs from these tissues were isolated by the
acid guanidinium-phenol-chloroform method (Chomczynski
and Sacchi, 1987). Isolated RNAs were reverse transcribed to
cDNA using random hexamers (Pharmacia, Uppsala,
Sweden). The 16 sets of PCR primers shown in Table II and
Figure 1 were synthesised according to the RB cDNA
sequence described by McGee et al. (1989) using an Applied
Biosystems model of 392 DNA synthesiser. These primers
were designed to cover the coding region from exons 1 to 27
of the RB gene. The T7 RNA polymerase promoter
sequence, TAATACGACTCACTATAGGG, was attached to
the 5' end of each upstream PCR primer to produce a
single-strand RNA with the same sequence as the sense
strand of the cDNA. PCR with each primer set provided
PCR products of 150-300 base pairs, covering overlapping
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Table I Clinical profile of bladder cancer and mutation of the RB gene
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aLOH: H, homozygous (uninformative); +, LOH positive; -, heterozygous; NE, not
examined. Primer set used in PCR-LOH assays was as follows: upstream, 5' TTCC-
AATGAAGAACAAATGG-3'; downstream, 5'GCAATTGCACAATCCAAGTT-3',
originally reported by McGee et al. (1990). bAAATlT (Lys-Phe)->ATT(Ile). cRecur-
rent case. dND, not detected. eNovel stop codon (TGA) at codon 695 caused by these
deletions.
Table II PCR primer sets for the RB gene
Nucleotide
Set Exon Sequence ofprimers number
a 1 5' T7a-CTCTCGTCAGGCTTGAGTTT 3' 266-285
4 5' ATGGACACTGATTTCTATGT 3' 525-506
b 3 5' T7-TTGACCTAGATGAGATGTCG 3' 461-480
6 5' GAAACTTTTAGCACCAATGC 3' 719-700
c 5 5' T7-ACACAACCCAGCAGTTCGAT 3' 661-680
8 5' TGCTATCCGTGCACTCCTGT 3' 930-911
d 8 5' T7-CCCATTAATGGTTCACCTCG 3' 871-890
10 5' GAAAGATTTTCAACCTCTGG 3' 1091-1072
e 9 5' T7-GGACTTGTAACATCTAATGG 3' 1048-1067
12 5' CATAACAGTCCTAACTGGAG 3' 1275-1256
f 11 5' T7-CCACACACTCCAGTTAGGAC 3' 1249-1268
13 5' CTGTCCCACAGCTlTTAGCAA 3' 1446-1427
g 13 5' T7-TAAAGCTGTGGGACAGGGTT 3' 1431-1450
16 5' TTACAACCTCAAGAGCGCAC 3' 1621-1602
h 16 5' T7-TCTTTATTGGCGTGCGCTCT 3' 1591-1610
17 5' CTTGTCAAGTTGCCTTCTGC 3' 1769-1750
17 5' T7-GGAACAGATTTGTCTTTCCC 3' 1663-1682
18 5' AATCTGAGAGCCATGCAAGG 3' 1837-1818
17 5' T7-TCATGGAATCCCTTGCATGG 3' 1808-1827
19 5' TTTACACGCGTAGTTGAACC 3' 2006-1987
k 18 5' T7-TCACACTGCAGCAGAT 3' 1935-1950
20 5' GAGATAGGCTAGCCGATACA 3' 2118-2099
19 5' T7-CGCGTGTAAATTCTACTGCA 3' 1997-2016
21 5' ATTTGGTCCAAATGCCTGTC 3' 2246-2227
m 20 5' T7-CACACCCTGCAGAATGAGTA 3' 2194-2213
22 5' GAATGTCTCCTGAACAGC 3' 2355-2338
n 22 5' T7-ACAAGGATCTTCCTCATG 3' 2321-2338
23 5' ACTTGTAAGGGCTTCGAGGA 3' 2512-2493
o 23 5' T7-CCTCACATTCCTCGAAGCCCTTACA 3' 2485-2509
25 5' CACTTCTTTTGAGCACACGGTCGC 3' 2725-2702
p 24 5' T7-GGTGAATCATTCGGGACTTCTGAGA 3' 2644-2668
27 5' GCTT-TTGCATTCGTGTTCGAGTAGA 3' 2878-2854
aDenotes that the fixed T7 promoter sequence of TAATACGACTCACTATAGGG was
attached to the 5' end of each upstream PCR primer.
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Figure 1 Exon map of the RB gene and locations of PCR primers in RB cDNA.
segments (Figure 1, Table II). The PCR was run in a DNA
thermal cycler (Perkin Elmer Cetus, Norwalk, CT, USA) for
40 cycles using the following parameters; denatusation 95°C,
1 min; annealing 63°C, 1 min; elongation 72°C, 1 min. Ali-
quots of 3til of the 30 PCR products derived from their sets
ofPCR primers were analysed by agarose gel electrophoresis.
Each PCR product was then transcribed to RNA with T7
RNA polymerase (Pharmacia) as described by Danenberg et
al. (1992). Aliquots of 3 tl of the RNA transcripts produced
by T7 RNA polymerase were electrophoresed on a 6% poly-
acrylamide gel (acrylamide:bis-acrylamide 19:1) in a Hoefer
650 dual-cooled PAGE unit (Hoefer Scientific Instruments,
San Francisco, CA, USA). The -running conditions of gel
electrophoresis were 25 W per plate at 6-7°C with circulating
ice-cooled water, as described previously (Danenberg et al.,
1992). The resultant gels were then stained with ethidium
bromide and abnormal electrophoretic patterns were analys-
ed under UV light.
Ligation ofPCRproducts and DNA sequencing
PCR products were directly ligated to the plasmid vector,
pCR 1000, in the TA cloning system (InVitrogen, San Diego,
CA, USA), according to the manufacturer's protocol. At
least ten colonies of the ligated PCR products were sequenc-
ed with Sequenase version 2.0 (United States Biochemical,
Cleveland, OH, USA). The mutations were confirmed by the
same protocols of ligation of PCR products and DNA
sequencing.
RFLP analysis
DNA was extracted using a model 341 nucleic acid
purification system (Applied Biosystems) from tissue samples.
When genomic DNAs from both tumours and normal cells
from venous blood from the same patients were available,
DNA was amplified using a primer set flanking an XbaI
RFLP site within intron 17 of the RB gene originally
reported by McGee et al. (1990) (Table I). The PCR condi-
tions were the same as for amplification of cDNA for exons
of the RB gene. These PCR products were digested with
XbaI (Takara Shuzo, Kyoto, Japan) into the two fragments
of 630 and 315 bp if its recognition site (TCTAGA) was
present. LOH appears as loss of the cleaved (630 + 315) or
the uncleaved (945) allele in the tumour.
Results
SSCP andsequence analysis
We electrophoresed T7 transcription products from PCR
samples derived from primer set (a) to (p) for RNA-SSCP
analysis. The results of 30 bladder cancer samples are sum-
marised in Table I. SSCP analysis revealed ten tumour sam-
ples suggestive of a mutation (Figure 2). Sequence studies of
these ten PCR products revealed single missense mutations in
five samples, small deletions in three samples (Figure 3, Table
t t
Figure 2 RNA-SSCP analysis of human bladder cancers with
primer set (e). Abnormal electrophoretic patterns (arrowheads)
are observed in cases 5 and 18.
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Figure 3 The DNA sequences of PCR products of case 18. The
point mutation was identified, resulting in a change from arginine
(CGG) to tryptophan (TGG) at codon 661 in the region of exon
20.
I) and no mutations in two samples. The types of point
mutations were a T to G transversion at the second position
of codon 138 (exon 4), a T to C transition at the second
position of codon 158 (exon 4), an A to G transition at the
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first position of codon 208 (exon 7), a C to T transition at
the first position of codon 661 (exon 20) and an A to G
transition at the first position of codon 794 (exon 23). Two
cases with single base pair deletions were identified at the
second or third position of codon 677 (exon 20) and at the
first position of codon 693 (exon 20), and both these dele-
tions resulted in generation of a novel stop codon at codon
695 in exon 20. The remaining one case with mutation was
found to have a deletion of 3 bp (AAT) (codons 896 to 897)
in exon 26. Comparisons of these sequences with DNA from
matching normal tissues confirmed that the alterations were
somatic events.
RB gene mutations were found in one (10%) of ten low-
grade (grade 1) tumours, four (50%) of eight intermediate-
grade (grade 2) tumours and three (25%) of 12 high-grade
(grade 3) tumours. In relation to pathological stages, four
(21%) of 19 superficial (pTa and PT1) and four (36%) of all
invasive (pT2 or greater), including two (33%) of six cases
with metastases, bladder cancers showed RB gene mutations.
There were no mutations in all the five cases with recurrent
bladder cancer.
Allelic loss ofthe RB gene
To detect RB-LOH, we used RFLP assays based on the
PCR. Allelic loss of the RB gene was detected in five (33%)
of 15 informative cases, including three cases with RB gene
mutations (Figure 4, Table I). However, two cases with RB
mutation did not have LOH.
Discussion
We investigated structural alterations of the RB gene in
tissue specimens of 30 human bladder cancers by use ofrapid
and sensitive RNA-SSCP analysis. We found eight mutated
cases, including five ofsingle missense mutations and three of
small deletions, and these mutations were found in low-grade
and low-stage tumours as well as in high-grade and invasive
tumours.
Several reports have identified the occurrence of RB gene
alterations mainly in retinoblastoma (Dunn et al., 1989;
Yandell et al., 1989) and small-cell lung cancer (Yandell et
al., 1989; Horowitz et al., 1990; Mori et al., 1990). These
mutations included small deletions and single point muta-
tions. Most of them occurred in the ElA-binding region of
the RB gene; in particular, those in lung cancer occurred
only within exons 20-23 of this gene.
So far as we know, no systematic studies have examined
structural alterations of the RB gene in human bladder
cancer. Only one report has shown one tumour with an A to
G transition at intron 21 resulting in loss of a splicing
acceptor site for exon 21 (Horowitz et al., 1989). Horowitz et
al. (1990) also showed inactivation of the RB gene in bladder
cancer cell lines by Southern blot analysis. Ishikawa et al.
(1991) demonstrated the existence of alterations of the RB
protein in human bladder cancer by Western blot analysis or
Figure
4 LOH demonstrated by PCR in cases 19 and 23. These
products were run on an agarose gel, which was stained with
ethidium bromide. N, normal tissue; T, tumour; M, marker.
immunohistochemical staining. Since these studies showed
that RB abnormalities were mainly observed in high-grade or
high-stage bladder cancers, RB gene mutations were sug-
gested to occur as late events. Several reports confirmed these
findings and further suggested that altered RB expression
might be useful clinical indicators for bladder cancers
(Cordon-Cardo et al., 1992; Logothetis et al., 1992). How-
ever, a recent report by Xu et al. (1993) showed that a
portion of low-grade or superficial bladder cancers had loss
of RB protein expression, although the loss was more fre-
quently seen in high-grade or invasive tumours. The present
study systematically analysing the abnormalities in the entire
coding region of the RB gene revealed the presence of RB
gene mutations irrespective of tumour grade and stage.
Therefore, RB gene alterations themselves were not specific
to high-grade or invasive bladder cancers.
Three mutations in this study occurred in the region of
exon 20, which encodes the parts of ElA-binding region of
the RB gene and is regarded as a 'hot-spot' in several malig-
nancies. In the five other cases RB gene mutations were
found in exons 4, 7, 23 and 26 which are outside this region.
The biological significance of these regions has not been
determined to date. Thus, the importance of the mutations in
these regions needs to be clarified.
We also examined allelic loss of the RB gene in this study.
Cairns et al. (1991) reported frequent loss of the RB gene in
162 bladder tumours using Southern blot analysis. That
report showed that 3% of low-grade, 32% of intermediate-
grade, 56% of high-grade, 4% of superficial and 57% of
invasive bladder cancers had LOH at the RB locus, and
concluded that RB-LOH strongly correlated with both
tumour grade and muscle invasion. The incidence of RB loss
in our results is similar to Cairns' results, but two mutated
cases without LOH were identified. This discrepancy might
be attributable to the possibility that normal tissues con-
taminated the tumour samples so that LOH could not be
detected. However, separate RB mutations could have occur-
red in each RB allele.
We reported previously that structural alterations in the
p53 tumour-suppressor gene occurred in the same 25 bladder
cancer samples (cases 1-25) as detected by the RNA-SSCP
analysis used here (Miyamoto et al., 1993). Although p53
gene mutations were detected in six cases (cases 1, 6, 14, 21,
22 and 25), only one case has mutations of both the p53 and
the RB genes (case 1). In addition, p53 alterations were
mostly detected in high grade and high stage bladder cancers.
In contrast, RB alterations were detected in low-grade and
non-invasive tumours as well as in high-grade and invasive
tumours in the present study. It is suggested that mutations
of the RB gene are involved in earlier steps of bladder
carcinogenesis than those of the p53 gene.
RB gene mutations detected by RNA-SSCP analysis in
the region of exons 1-27 in 30 bladder cancer tissues were
found in eight (27%) cases. This frequency might be under-
estimated for several reasons. One is amplification of cDNA
from the normal stromal component of the tumour or con-
tamination by normal tissue. Another is the fact that the
SSCP method may not identify all mutations. It has recently
been suggested that immunohistochemical staining is more
sensitive and specific than examining RB gene mutations by
molecular techniques (Zhang et al., 1994). Therefore,
immunohistochemical analysis should be performed both to
clarify the relative value of these approaches and to streng-
then the significance of the observation of RB mutations.
Finally, coexistence of abnormalities of multiple tumour-
suppressor genes are commonly found in cancers (Murakami
et al., 1991), and cooperative roles for the RB and the p53
genes have been suggested (Shay et al., 1991). Further studies
are required to clarify the multistep process of bladder cancer
development in relation to the alterations of tumour-
suppressor genes, and it will be interesting to see whether
mutations of the RB gene as well as other tumour-suppressor
genes can be used as clinical predictors for determining prog-
nosis and guiding treatment in patients with bladder
cancer.RBgne in bladder cancer
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